The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19
Evidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of great concern for individuals living with these conditions, and a major challenge for global healthcare systems and...
Gespeichert in:
Veröffentlicht in: | Frontiers in immunology 2020-08, Vol.11, p.1991 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | 1991 |
container_title | Frontiers in immunology |
container_volume | 11 |
creator | Callender, Lauren A Curran, Michelle Bates, Stephanie M Mairesse, Maelle Weigandt, Julia Betts, Catherine J |
description | Evidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of great concern for individuals living with these conditions, and a major challenge for global healthcare systems and biomedical research. Not all comorbidities confer the same risk, however, many affect the function of the immune system, which in turn directly impacts the response to COVID-19. Furthermore, the myriad of drugs prescribed for these comorbidities can also influence the progression of COVID-19 and limit additional treatment options available for COVID-19. Here, we review immune dysfunction in response to SARS-CoV-2 infection and the impact of pre-existing comorbidities on the development of COVID-19. We explore how underlying disease etiologies and common therapies used to treat these conditions exacerbate COVID-19 progression. Moreover, we discuss the long-term challenges associated with the use of both novel and repurposed therapies for the treatment of COVID-19 in patients with pre-existing comorbidities. |
doi_str_mv | 10.3389/fimmu.2020.01991 |
format | Article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7437504</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_bbf97fbb70424781af0874eed1ba5beb</doaj_id><sourcerecordid>2441610403</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-5a8f1566c5ea86f67260bdda83c937f6042d8a83cc56c0de7b7d429e808ab1423</originalsourceid><addsrcrecordid>eNpVkUtP3DAURqOqqCDKvqvKy24y9St2sqlUTSlEQqJCtFvLj-vBKImndoLg39czQxF449d3j691quoTwSvG2u6rD-O4rCimeIVJ15F31QkRgteMUv7-1fq4Osv5HpfBO8ZY86E6ZrTDjEtxUt3c3gHqx622M4oe_UpQw2PIc5g2aB3HmExwYQ6QkZ4cKuGkt7DMwaJ-miE9wDSHOGUUJ7S-_tP_qEn3sTryeshw9jyfVr9_nt-uL-ur64t-_f2qtlzQuW5060kjhG1At8ILSQU2zumW2Y5JLzCnrt3tbCMsdiCNdJx20OJWG8IpO636A9dFfa-2KYw6Pamog9ofxLRROpVOB1DG-E56Y2SBctkS7XErOYAjRjcGTGF9O7C2ixnB2fKtpIc30Lc3U7hTm_igJGeywbwAvjwDUvy7QJ7VGLKFYdATxCUryjkRBHPMShQfojbFnBP4l2cIVjuzam9W7cyqvdlS8vl1ey8F_z2yfzR8oGc</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2441610403</pqid></control><display><type>article</type><title>The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19</title><source>Open Access: DOAJ - Directory of Open Access Journals</source><source>MEDLINE</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><source>PubMed Central Open Access</source><creator>Callender, Lauren A ; Curran, Michelle ; Bates, Stephanie M ; Mairesse, Maelle ; Weigandt, Julia ; Betts, Catherine J</creator><creatorcontrib>Callender, Lauren A ; Curran, Michelle ; Bates, Stephanie M ; Mairesse, Maelle ; Weigandt, Julia ; Betts, Catherine J</creatorcontrib><description>Evidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of great concern for individuals living with these conditions, and a major challenge for global healthcare systems and biomedical research. Not all comorbidities confer the same risk, however, many affect the function of the immune system, which in turn directly impacts the response to COVID-19. Furthermore, the myriad of drugs prescribed for these comorbidities can also influence the progression of COVID-19 and limit additional treatment options available for COVID-19. Here, we review immune dysfunction in response to SARS-CoV-2 infection and the impact of pre-existing comorbidities on the development of COVID-19. We explore how underlying disease etiologies and common therapies used to treat these conditions exacerbate COVID-19 progression. Moreover, we discuss the long-term challenges associated with the use of both novel and repurposed therapies for the treatment of COVID-19 in patients with pre-existing comorbidities.</description><identifier>ISSN: 1664-3224</identifier><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2020.01991</identifier><identifier>PMID: 32903476</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Betacoronavirus - drug effects ; Comorbidity ; Coronavirus Infections - drug therapy ; Coronavirus Infections - mortality ; Coronavirus Infections - pathology ; COVID-19 ; Humans ; Immunology ; immunology and infectious diseases ; inflammation ; inflammatory diseases ; Pandemics ; Pneumonia, Viral - drug therapy ; Pneumonia, Viral - mortality ; Pneumonia, Viral - pathology ; Risk ; Risk Factors ; SARS-CoV-2 ; virus immunity</subject><ispartof>Frontiers in immunology, 2020-08, Vol.11, p.1991</ispartof><rights>Copyright © 2020 Callender, Curran, Bates, Mairesse, Weigandt and Betts.</rights><rights>Copyright © 2020 Callender, Curran, Bates, Mairesse, Weigandt and Betts. 2020 Callender, Curran, Bates, Mairesse, Weigandt and Betts</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-5a8f1566c5ea86f67260bdda83c937f6042d8a83cc56c0de7b7d429e808ab1423</citedby><cites>FETCH-LOGICAL-c462t-5a8f1566c5ea86f67260bdda83c937f6042d8a83cc56c0de7b7d429e808ab1423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437504/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437504/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,27926,27927,53793,53795</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32903476$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Callender, Lauren A</creatorcontrib><creatorcontrib>Curran, Michelle</creatorcontrib><creatorcontrib>Bates, Stephanie M</creatorcontrib><creatorcontrib>Mairesse, Maelle</creatorcontrib><creatorcontrib>Weigandt, Julia</creatorcontrib><creatorcontrib>Betts, Catherine J</creatorcontrib><title>The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19</title><title>Frontiers in immunology</title><addtitle>Front Immunol</addtitle><description>Evidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of great concern for individuals living with these conditions, and a major challenge for global healthcare systems and biomedical research. Not all comorbidities confer the same risk, however, many affect the function of the immune system, which in turn directly impacts the response to COVID-19. Furthermore, the myriad of drugs prescribed for these comorbidities can also influence the progression of COVID-19 and limit additional treatment options available for COVID-19. Here, we review immune dysfunction in response to SARS-CoV-2 infection and the impact of pre-existing comorbidities on the development of COVID-19. We explore how underlying disease etiologies and common therapies used to treat these conditions exacerbate COVID-19 progression. Moreover, we discuss the long-term challenges associated with the use of both novel and repurposed therapies for the treatment of COVID-19 in patients with pre-existing comorbidities.</description><subject>Betacoronavirus - drug effects</subject><subject>Comorbidity</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronavirus Infections - mortality</subject><subject>Coronavirus Infections - pathology</subject><subject>COVID-19</subject><subject>Humans</subject><subject>Immunology</subject><subject>immunology and infectious diseases</subject><subject>inflammation</subject><subject>inflammatory diseases</subject><subject>Pandemics</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Pneumonia, Viral - mortality</subject><subject>Pneumonia, Viral - pathology</subject><subject>Risk</subject><subject>Risk Factors</subject><subject>SARS-CoV-2</subject><subject>virus immunity</subject><issn>1664-3224</issn><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNpVkUtP3DAURqOqqCDKvqvKy24y9St2sqlUTSlEQqJCtFvLj-vBKImndoLg39czQxF449d3j691quoTwSvG2u6rD-O4rCimeIVJ15F31QkRgteMUv7-1fq4Osv5HpfBO8ZY86E6ZrTDjEtxUt3c3gHqx622M4oe_UpQw2PIc5g2aB3HmExwYQ6QkZ4cKuGkt7DMwaJ-miE9wDSHOGUUJ7S-_tP_qEn3sTryeshw9jyfVr9_nt-uL-ur64t-_f2qtlzQuW5060kjhG1At8ILSQU2zumW2Y5JLzCnrt3tbCMsdiCNdJx20OJWG8IpO636A9dFfa-2KYw6Pamog9ofxLRROpVOB1DG-E56Y2SBctkS7XErOYAjRjcGTGF9O7C2ixnB2fKtpIc30Lc3U7hTm_igJGeywbwAvjwDUvy7QJ7VGLKFYdATxCUryjkRBHPMShQfojbFnBP4l2cIVjuzam9W7cyqvdlS8vl1ey8F_z2yfzR8oGc</recordid><startdate>20200811</startdate><enddate>20200811</enddate><creator>Callender, Lauren A</creator><creator>Curran, Michelle</creator><creator>Bates, Stephanie M</creator><creator>Mairesse, Maelle</creator><creator>Weigandt, Julia</creator><creator>Betts, Catherine J</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20200811</creationdate><title>The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19</title><author>Callender, Lauren A ; Curran, Michelle ; Bates, Stephanie M ; Mairesse, Maelle ; Weigandt, Julia ; Betts, Catherine J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-5a8f1566c5ea86f67260bdda83c937f6042d8a83cc56c0de7b7d429e808ab1423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Betacoronavirus - drug effects</topic><topic>Comorbidity</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronavirus Infections - mortality</topic><topic>Coronavirus Infections - pathology</topic><topic>COVID-19</topic><topic>Humans</topic><topic>Immunology</topic><topic>immunology and infectious diseases</topic><topic>inflammation</topic><topic>inflammatory diseases</topic><topic>Pandemics</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Pneumonia, Viral - mortality</topic><topic>Pneumonia, Viral - pathology</topic><topic>Risk</topic><topic>Risk Factors</topic><topic>SARS-CoV-2</topic><topic>virus immunity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Callender, Lauren A</creatorcontrib><creatorcontrib>Curran, Michelle</creatorcontrib><creatorcontrib>Bates, Stephanie M</creatorcontrib><creatorcontrib>Mairesse, Maelle</creatorcontrib><creatorcontrib>Weigandt, Julia</creatorcontrib><creatorcontrib>Betts, Catherine J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Callender, Lauren A</au><au>Curran, Michelle</au><au>Bates, Stephanie M</au><au>Mairesse, Maelle</au><au>Weigandt, Julia</au><au>Betts, Catherine J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19</atitle><jtitle>Frontiers in immunology</jtitle><addtitle>Front Immunol</addtitle><date>2020-08-11</date><risdate>2020</risdate><volume>11</volume><spage>1991</spage><pages>1991-</pages><issn>1664-3224</issn><eissn>1664-3224</eissn><abstract>Evidence from the global outbreak of SARS-CoV-2 has clearly demonstrated that individuals with pre-existing comorbidities are at a much greater risk of dying from COVID-19. This is of great concern for individuals living with these conditions, and a major challenge for global healthcare systems and biomedical research. Not all comorbidities confer the same risk, however, many affect the function of the immune system, which in turn directly impacts the response to COVID-19. Furthermore, the myriad of drugs prescribed for these comorbidities can also influence the progression of COVID-19 and limit additional treatment options available for COVID-19. Here, we review immune dysfunction in response to SARS-CoV-2 infection and the impact of pre-existing comorbidities on the development of COVID-19. We explore how underlying disease etiologies and common therapies used to treat these conditions exacerbate COVID-19 progression. Moreover, we discuss the long-term challenges associated with the use of both novel and repurposed therapies for the treatment of COVID-19 in patients with pre-existing comorbidities.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>32903476</pmid><doi>10.3389/fimmu.2020.01991</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1664-3224 |
ispartof | Frontiers in immunology, 2020-08, Vol.11, p.1991 |
issn | 1664-3224 1664-3224 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7437504 |
source | Open Access: DOAJ - Directory of Open Access Journals; MEDLINE; PubMed Central; EZB Electronic Journals Library; PubMed Central Open Access |
subjects | Betacoronavirus - drug effects Comorbidity Coronavirus Infections - drug therapy Coronavirus Infections - mortality Coronavirus Infections - pathology COVID-19 Humans Immunology immunology and infectious diseases inflammation inflammatory diseases Pandemics Pneumonia, Viral - drug therapy Pneumonia, Viral - mortality Pneumonia, Viral - pathology Risk Risk Factors SARS-CoV-2 virus immunity |
title | The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T23%3A00%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Impact%20of%20Pre-existing%20Comorbidities%20and%20Therapeutic%20Interventions%20on%20COVID-19&rft.jtitle=Frontiers%20in%20immunology&rft.au=Callender,%20Lauren%20A&rft.date=2020-08-11&rft.volume=11&rft.spage=1991&rft.pages=1991-&rft.issn=1664-3224&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2020.01991&rft_dat=%3Cproquest_doaj_%3E2441610403%3C/proquest_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2441610403&rft_id=info:pmid/32903476&rft_doaj_id=oai_doaj_org_article_bbf97fbb70424781af0874eed1ba5beb&rfr_iscdi=true |